Adiponectin and visfatin may serve as diagnosis markers for metabolic syndrome in Uygur population

作者：Chang, Xi; Jiao, Yi; Lu, Jianfei; Wang, Yanjiao; Abudureyimu, Kelim; Zhang, Cheng; Nuermaimaiti, Nuerbiye; Gong, Xian; Aisa, Yiliyasi; Guan, Yaqun^*

来源：International Journal of Clinical and Experimental Medicine, 2014, 7(11): 4322-4326.

• Metabolic syndrome
• adipocytokine
• adiponectin
• visfatin

Objectives: This study is to determine if two adipocytokines, adiponectin and visfatin, can be used as diagnosis markers for metabolic syndrome (MS) in Uygur population. Methods: Sixty-two MS patients and 41 control individuals with normal body weights were enrolled in this study. Abdominal subcutaneous and omental adipose tissues were collected for determination of biochemical indices. The adipokines serum levels were determined by enzyme-linked immunosorbent assay (ELISA). Blood were collected from the MS patients and the control individuals and extracted proteins and RNAs subjected to western blot analysis and real-time PCR to determine adiponectin and visfatin expression, respectively. Results: ELISA indicated that the serum adiponectin in the MS group was decreased (0.59 +/- 0.21 versus 0.49 +/- 0.18) in comparison with the control group (P < 0.05). But the serum visfatin in the MS group were increased (1.07 +/- 0.41 versus 1.25 +/- 0.32) when compared with the control group (P < 0.05). The western blot revealed decreased adiponectin and increased visfatin expression in the MS patients when compared with the normal controls. Further real-time RT-PCR analysis showed that the adiponectin and visfatin expression are altered via a transcriptional mechanism. Conclusions: Adiponectin and visfatin might be used as diagnosis markers of MS in Uygur population.

• 出版日期2014
• 单位新疆维吾尔自治区人民医院; 新疆医科大学